|
Thursday, Sept. 5, 2019
|
|
7–8 a.m.
|
Registration and Breakfast
|
|
8 a.m.
|
Opening Remarks
Franco Marincola, MD – Refuge Biotechnologies
|
|
Session I: State of the Field of Adoptive Cellular Therapy
|
|
Time:
|
8:05–9:35 a.m.
|
|
Co-Chairs
|
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
|
|
8:05 a.m.
|
Introduction
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Katayoun Rezvani, MD, PhD – The University of Texas MD Anderson Cancer Center
|
|
8:25 a.m.
|
T cells Recognizing Antigen Through Native or Chimeric Receptors
Helen E. Heslop, MD – Baylor College of Medicine
|
|
9:15 a.m.
|
Q&A
|
|
9:35 a.m.
|
Break
|
|
Session II: External Circumstantial Factors
|
|
Time:
|
9:50–11:40 a.m.
|
|
Co-Chairs:
|
Alessandra Cesano, MD, PhD – ESSA Pharma Inc.
Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
|
|
9:50 a.m.
|
CAR T cell Product Heterogeneity and Response to Treatment
J. Joseph Melenhorst, PhD – University of Pennsylvania
|
|
10:10 a.m.
|
Effects of Co-Morbidities and Concomitant Medications on Immunotherapy Efficacy and Safety
Michael N. Liebman, PhD – IPQ Analytics, LLC
|
|
10:30 a.m.
|
 Learning to Harness Cancer-Curing Poop as a Group: Collaborative Microbiome Research and Beyond at the Parker Institute for Cancer Immunotherapy
Christine Spencer, PhD – Parker Institute for Cancer Immunotherapy
|
|
10:50 a.m.
|
Microbiome: Methods and New Technologies for Sample Collection and Assay Standardization
Tessa Andermann, MD – Stanford University
|
|
11:10 a.m.
|
Panel Discussion
|
|
11:40 a.m.
|
Break
|
|
Session III: Emerging Ideas and New Concepts
|
|
Time:
|
11:55 a.m.–12:55 p.m.
|
|
Co-Chairs:
|
Francesco M. Marincola, MD – Refuge Biotechnologies, Inc.
Kyung-Ho Roh, PhD – University of Alabama in Huntsville
|
|
11:55 a.m.
|
Detection and Activation of CAR-T Cells Using Standardized Models
Kyung-Ho Roh, PhD – University of Alabama in Huntsville
|
|
12:15 p.m.
|
Conditional Regulation of CAR T
Stanley Qi, PhD – Stanford University
|
|
12:35 p.m.
|
T cell Reprogramming
Luca Gattinoni, MD – National Cancer Institute
|
|
12:55 p.m.
|
Lunch
|
|
Session IV: Improving Risk and Benefit Profile of Adoptive Cellular Therapy
|
|
Time:
|
2–5 p.m.
|
|
Co-Chairs:
|
Prasad S. Adusumilli, MD, FACS, FCCP – Memorial Sloan Kettering Cancer Center
David M. Barrett, MD, PhD – Children’s Hospital of Philadelphia
|
|
2 p.m.
|
Understanding the Biology of CAR T Resistance
Nathan Singh, MD – Washington University
|
|
2:20 p.m.
|
Optimizing Synthetic Receptors to Prevent Relapse after Genetically Modified T Cell Therapy for Leukemia
Terry Fry, MD – Children’s Hospital Colorado
|
|
2:40 p.m.
|
Beyond CAR T 2.0: Strategy to Reduce Toxicity – Safety Switches and Synthetic Biology
Julien Valton, PhD – Cellectis, Inc.
|
|
3 p.m.
|
Beyond CAR T 2.0: Off the Shelf CAR T
Christopher Haqq, MD, PhD – Atara Biotherapeutics
|
|
3:20 p.m.
|
Break
|
|
3:35 p.m.
|
Beyond CAR T: NKT cell Platform for Adoptive cell Therapy
Lenoid Metelitsa, MD, PhD – Baylor College of Medicine
|
|
3:55 p.m.
|
Manufacturing and Analytics in CAR T cell Technology: CAR T cell Product Characterization and Function
Xiuyan Wang, PhD – Memorial Sloan Kettering Cancer Center
|
|
4:15 p.m.
|
Impact of the Tumor Microenvironment for CAR-T cell Therapy Efficacy
Jérôme Galon, PhD – INSERM, Sorbonne Universites Paris
|
|
4:35 p.m.
|
Panel Discussion
|
|
4:55 p.m.
|
Closing
|
|
5:00 p.m.
|
Adjourn
|
|
|